Abstract
EGF-modified Au NP-Pc 4 conjugates showed 10-fold improved selectivity to the brain tumor compared to untargeted conjugates. The hydrophobic photodynamic therapy drug Pc 4 can be delivered efficiently into glioma brain tumors by EGF peptide-targeted Au NPs. Compared to the untargeted conjugates, EGF-Au NP-Pc 4 conjugates showed 10-fold improved selectivity to the brain tumor. This delivery system holds promise for future delivery of a wider range of hydrophobic therapeutic drugs for the treatment of hard-to-reach cancers.
Keywords:
brain tumors; gold nanoparticles; nanomedicine; photodynamic therapy; targeted delivery.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Animals
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / metabolism*
-
Cell Line, Tumor
-
Delayed-Action Preparations
-
Epidermal Growth Factor / chemistry
-
Epidermal Growth Factor / pharmacokinetics*
-
ErbB Receptors / metabolism
-
Glioma / drug therapy
-
Glioma / metabolism
-
Gold / therapeutic use*
-
Humans
-
Hydrophobic and Hydrophilic Interactions
-
Indoles / administration & dosage
-
Indoles / chemistry
-
Isoindoles
-
Metal Nanoparticles / therapeutic use*
-
Metal Nanoparticles / ultrastructure
-
Mice
-
Nanocapsules / chemistry
-
Nanocapsules / ultrastructure
-
Nanoconjugates / therapeutic use
-
Nanoconjugates / ultrastructure
-
Photochemotherapy / methods*
-
Photosensitizing Agents / administration & dosage
-
Photosensitizing Agents / chemistry
-
Treatment Outcome
Substances
-
Delayed-Action Preparations
-
Indoles
-
Isoindoles
-
Nanocapsules
-
Nanoconjugates
-
Photosensitizing Agents
-
Epidermal Growth Factor
-
Gold
-
ErbB Receptors
-
phthalocyanine